BRPI1010852A2 - compostos antivirais heterocíclicos - Google Patents

compostos antivirais heterocíclicos

Info

Publication number
BRPI1010852A2
BRPI1010852A2 BRPI1010852A BRPI1010852A BRPI1010852A2 BR PI1010852 A2 BRPI1010852 A2 BR PI1010852A2 BR PI1010852 A BRPI1010852 A BR PI1010852A BR PI1010852 A BRPI1010852 A BR PI1010852A BR PI1010852 A2 BRPI1010852 A2 BR PI1010852A2
Authority
BR
Brazil
Prior art keywords
antiviral compounds
heterocyclic antiviral
heterocyclic
compounds
antiviral
Prior art date
Application number
BRPI1010852A
Other languages
English (en)
Inventor
Xavier Talamas Francisco
De Vicente Fidalgo Javier
Li Jim
Paul Gergely Taygerly Joshua
Craig Schoenfeld Ryan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1010852A2 publication Critical patent/BRPI1010852A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BRPI1010852A 2009-06-09 2010-06-08 compostos antivirais heterocíclicos BRPI1010852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18546009P 2009-06-09 2009-06-09
US26335109P 2009-11-21 2009-11-21
PCT/EP2010/057958 WO2010142656A1 (en) 2009-06-09 2010-06-08 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
BRPI1010852A2 true BRPI1010852A2 (pt) 2019-09-24

Family

ID=42288900

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010852A BRPI1010852A2 (pt) 2009-06-09 2010-06-08 compostos antivirais heterocíclicos

Country Status (24)

Country Link
US (2) US8026253B2 (pt)
EP (1) EP2440528B1 (pt)
JP (1) JP5612678B2 (pt)
KR (1) KR101431343B1 (pt)
CN (1) CN102803216B (pt)
AR (1) AR077004A1 (pt)
AU (1) AU2010257592B2 (pt)
BR (1) BRPI1010852A2 (pt)
CA (1) CA2764141C (pt)
CO (1) CO6400218A2 (pt)
CR (1) CR20110605A (pt)
EC (1) ECSP11011513A (pt)
ES (1) ES2525254T3 (pt)
IL (1) IL216412A (pt)
MA (1) MA33360B1 (pt)
MX (1) MX2011013209A (pt)
MY (1) MY157435A (pt)
NZ (1) NZ596646A (pt)
PE (2) PE20151092A1 (pt)
RU (1) RU2540332C2 (pt)
SG (1) SG176762A1 (pt)
TW (1) TWI428332B (pt)
WO (1) WO2010142656A1 (pt)
ZA (1) ZA201108921B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519661A (ja) * 2009-03-06 2012-08-30 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
CN102971305B (zh) * 2010-07-07 2016-02-03 弗·哈夫曼-拉罗切有限公司 抗病毒的杂环化合物
RU2572835C2 (ru) * 2010-08-13 2016-01-20 Ф. Хоффманн-Ля Рош Аг Производные (4-метилсульфониламинофенил)-хинолина, полезные при лечении гепатита с
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JP6377245B2 (ja) * 2014-03-24 2018-08-22 グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド Smo阻害剤としてのキノリン誘導体
EP3328839A1 (en) * 2015-07-30 2018-06-06 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
BR122022012697B1 (pt) 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7874541B2 (ja) * 2019-09-16 2026-06-16 ノバルティス アーゲー 接着分解剤及びその使用方法
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
WO2022091048A1 (en) * 2020-10-30 2022-05-05 Integral Biosciences Private Limited Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB558009A (en) * 1942-05-08 1943-12-15 Harold Coates Quinoline derivatives
NZ235444A (en) * 1989-09-26 1992-07-28 Sumitomo Chemical Co Heterocyclically-substituted 1,2,3,6 tetrahydropyrimidine 2,6-diones, intermediates and herbicides
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
WO2001085172A1 (en) * 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
RU2010111550A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-замещенные индольные производные для лечения вирусных инфекций
EP2195317B1 (en) 2007-08-29 2012-01-18 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
JP5179585B2 (ja) 2007-08-29 2013-04-10 メルク・シャープ・アンド・ドーム・コーポレーション 四環系インドール誘導体およびその使用法
WO2009039134A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
AR070027A1 (es) 2007-09-17 2010-03-10 Abbott Lab Agentes anti-infecciosos contra el virus hcv
HRP20110632T1 (hr) 2007-09-17 2011-10-31 Abbott Laboratories N-fenil-diokso-hidropirimidini korisni kao inhibitori virusa hepatitisa c (hcv)
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
RU2552533C2 (ru) 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
RU2015144653A (ru) 2009-03-25 2018-12-29 Эббви Инк. Противовирусные соединения и их применения

Also Published As

Publication number Publication date
MA33360B1 (fr) 2012-06-01
AU2010257592B2 (en) 2014-11-13
US8487103B2 (en) 2013-07-16
EP2440528B1 (en) 2014-10-08
MX2011013209A (es) 2012-01-09
US8026253B2 (en) 2011-09-27
CN102803216A (zh) 2012-11-28
US20100311760A1 (en) 2010-12-09
MY157435A (en) 2016-06-15
TWI428332B (zh) 2014-03-01
AU2010257592A1 (en) 2011-12-15
CO6400218A2 (es) 2012-03-15
WO2010142656A1 (en) 2010-12-16
PE20151092A1 (es) 2015-08-06
AR077004A1 (es) 2011-07-27
KR20120016675A (ko) 2012-02-24
CA2764141A1 (en) 2010-12-16
ZA201108921B (en) 2014-05-28
RU2011153788A (ru) 2013-07-20
NZ596646A (en) 2014-01-31
SG176762A1 (en) 2012-01-30
IL216412A (en) 2015-01-29
CR20110605A (es) 2012-02-09
ES2525254T3 (es) 2014-12-19
ECSP11011513A (es) 2012-01-31
US20110300103A1 (en) 2011-12-08
HK1176070A1 (zh) 2013-07-19
IL216412A0 (en) 2012-02-29
EP2440528A1 (en) 2012-04-18
JP2012529461A (ja) 2012-11-22
KR101431343B1 (ko) 2014-08-19
TW201103906A (en) 2011-02-01
CN102803216B (zh) 2016-04-06
CA2764141C (en) 2016-11-15
PE20120937A1 (es) 2012-08-01
JP5612678B2 (ja) 2014-10-22
RU2540332C2 (ru) 2015-02-10

Similar Documents

Publication Publication Date Title
BR112012005616A2 (pt) compostos antivirais heterocíclicos
SMT201600351B (it) Composti antivirali
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
SMT201600008B (it) Composti di piridazinone
ATE539070T1 (de) Heterozyklische antivirale verbindungen
DK2427449T3 (da) Vinylindazolylforbindelser
BR112012006859A2 (pt) compostos
ECSP12011999A (es) Derivados benzamida sustituidos
IL216412A0 (en) Heterocyclic antiviral compounds
BRPI1013246A2 (pt) derivados de benzofuralina
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
DK2540728T3 (da) Heterocyklisk forbindelse
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI0821349A2 (pt) compostos antivirais heterocíclicos
DK2397480T3 (da) Diazepindionderivat
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI1013493A2 (pt) composto de pirimidina
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
DK2387580T3 (da) Deoxyactagardinderivater
BR112012010238A2 (pt) compostos heterocíclicos pesticidas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.